Regulatory milestones

Amgen Inc. (NASDAQ:AMGN) shed $0.77 to $56.61 last week after CMS released questions for a March 24 meeting that will review the use of erythropoiesis-stimulating agents (ESAs) to treat anemia in patients with chronic kidney disease (CKD). In the U.S., Amgen markets Aranesp darbepoetin alfa for cancer and renal indications and Epogen epoetin alfa for chronic renal failure. (see Online Links, A19).

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) was up $0.91 to $18.89 last week after FDA extended the PDUFA date to March 12 from March 5 for an NDA for exenatide once weekly to treat Type II diabetes. The product uses drug delivery technology from Alkermes Inc. (NASDAQ:ALKS), which lost $0.24 to $11.46...